SARS-CoV-2 变种和贝贝洛维玛:由计算研究揭示的免疫逃生机制
Rakesh Kumar Roy1, Madhur Sharma1, Niladri Patra1
1Department of Chemistry and Chemical Biology, Indian Institute of Technology (ISM) Dhanbad, Dhanbad - 826004, India. npatra2@iitism.ac.in.
Physical chemistry chemical physics : PCCP
|December 2, 2024
概括
在SARS-CoV-2受体结合域 (RBD) 中的突变降低了单克隆抗体bebtelovimab的疗效. 分子动力学模拟显示,由于特定的残留物变化,结合变化,影响抑制.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
背景情况:
- 通过ACE2受体,SARS-CoV-2受体结合域 (RBD) 对于病毒进入至关重要.
- 在RBD中的突变可以影响中和单克隆抗体的结合,从而损害治疗疗效.
- 贝贝特洛维马布是一种人类衍生的单克隆抗体,向SARS-CoV-2 RBD.
研究的目的:
- 使用分子动力学阐明贝贝托利维玛与SARS-CoV-2 RBD的结合机制.
- 调查RBD突变对贝贝洛维马布结合功效和位置的影响.
- 分析bebtelovimab与不同SARS-CoV-2变种的解结过程和结合能量.
主要方法:
- 用分子动力学 (MD) 模拟来研究贝贝洛维玛和SARS-CoV-2 RBD之间的相互作用.
- 改进的采样技术,特别是雨采样,被用来分析解绑路径.
- 对于野生类型,三角形和欧米克朗变体进行了绑定能量计算.
主要成果:
- 特定的残留物 (例如,440(N/K),Lys444,452(L/R),484(E/A),498(Q/R,THR500) 被确定为改变贝贝洛维玛的结合位置和突变后的疗效的关键.
- 贝贝托利维玛与RBD的结合疗效显示,野生型,三角型和奥米克朗变种的结合效率呈下降趋势.
- 发现突变直接或间接地破坏了抗体-RBD结合机制.
结论:
- RBD突变显著影响贝贝洛维玛的结合,减少其对SARS-CoV-2的抑制功能.
- 这项研究强调了新出现的病毒变体对抗体治疗的挑战.
- 了解这些分子相互作用对于开发下一代抗病毒战略至关重要.
相关概念视频
02:28Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K